Clinical Trial Search

Primary: Mean Area Under the Curve (AUC) of the Visual Analogue Scale (VAS). — 155.57; 185.27; 161.36; 126.59 pain intensity score*hr

Primary: Percentage of Participants With Treatment Emergent Adverse Events — 71.4; 83.9; 81.8 Percentage of Participants

Primary: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Month 3. — -2.96 mmHg

Primary: Intraocular Pressure at Week 1 — 19.0; 19.1; 18.0; 18.2 mmHg

Primary: Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the Unified Huntington's Disease Rating Scale [UHDRS] Motor Assessments) at…

Primary: CRIS-EPS: Comparison of Extent of Participation Scores Among iCBT, sCBT, and TAU Groups From Baseline to 1, 3, and 6 Month Follow Ups — 4.21; 4.18; 4.17; 4.52 score on a…

Primary: Percentage of Participants Who Develop a Booster Response to Tetanus Toxoid 4 Weeks After Tdap (Tetanus-diphtheria-pertussis) Vaccine Administration — 73.4; 73.6…

Primary: Percentage of Subjects Reporting Headache Pain Freedom — 85; 14 Participants — p=<0.001

Primary: Surgical Site Infection — 11; 10 Participants

Primary: Percentage of Patients Who Had Residual Cancer Found in at Least One LUM Imaging System Guided Shave Among All Patients. — 7.6 percentage of participants

Primary: Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. — 10; 10 Participants

Primary: Combined Assessment of Function and Survival (CAFS) — 0.51; 0.49 score on a scale — p=0.6208

Primary: Disease Progression as Assessed by the ALSFRS-R Total Score — -0.99; -1.00 points per month

Primary: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 — 34.4; 1.0 meters — p=<0.001

Primary: Percentage of Participants With an Investigators Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 — 6.1; 29.1; 33.4 Percentage…